Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $22.00 Price Target at Wedbush

Posted by Stanley Muller on Nov 4th, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective decreased by equities researchers at Wedbush from $25.00 to $22.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Wedbush‘s price target would suggest a potential upside of 30.09% from the stock’s current price.

Other analysts have also issued reports about the company. Evercore lowered Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective for the company. in a research report on Thursday, September 3rd. JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. Jefferies Financial Group dropped their price target on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Cantor Fitzgerald raised their price objective on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research note on Friday, September 18th. Finally, Morgan Stanley lifted their target price on shares of Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the stock an “equal weight” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $33.60.

Get Our Latest Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $16.91 on Wednesday. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.87 and a beta of 0.37. The company’s fifty day moving average is $16.64 and its two-hundred day moving average is $22.81. Ultragenyx Pharmaceutical has a 52-week low of $12.73 and a 52-week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. The business’s revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.81) earnings per share. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock valued at $127,561 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently bought and sold shares of RARE. Parallel Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares during the period. Sterling Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 102.4% in the 3rd quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,252 shares during the period. Leonteq Securities AG boosted its stake in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,333 shares during the period. Versant Capital Management Inc boosted its stake in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 573.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability guidance. It expects expense and workforce reductions to cut 2027 R&D spending by at least 50% compared with 2025. Ultragenyx third-quarter results and outlook
Positive Sentiment: The company said it has agreements to sell two Priority Review Vouchers for a combined $413 million, providing a substantial source of cash. FDA approvals of GENGLYCOS and FAYUVI were also announced during the quarter. Ultragenyx third-quarter results and outlook
Neutral Sentiment: Revenue rose 8.2% year over year to $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. The quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Ultragenyx third-quarter earnings results
Negative Sentiment: Despite year-over-year improvement, the $1.16 per-share loss was slightly wider than analysts’ roughly $1.10–$1.15 expected loss, and revenue of $173 million fell short of the $182.5 million consensus estimate. Ultragenyx Q3 loss and revenue results

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.